Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

Edward A. Weinstein(GlaxoSmithKline (United States)), Takahiro Yano(GlaxoSmithKline (United States)), Linsheng Li(GlaxoSmithKline (United States)), David Avarbock(GlaxoSmithKline (United States)), Andrew Avarbock(GlaxoSmithKline (United States)), Douglas L. Helm(GlaxoSmithKline (United States)), Andrew A. McColm(GlaxoSmithKline (United States)), Ken Duncan(GlaxoSmithKline (United States)), John T. Lonsdale(GlaxoSmithKline (United States)), Harvey Rubin(GlaxoSmithKline (United States))
Proceedings of the National Academy of Sciences
March 14, 2005
Cited by 293Open Access
Full Text

Abstract

Mycobacterium tuberculosis (Mtb) is an obligate aerobe that is capable of long-term persistence under conditions of low oxygen tension. Analysis of the Mtb genome predicts the existence of a branched aerobic respiratory chain terminating in a cytochrome bd system and a cytochrome aa(3) system. Both chains can be initiated with type II NADH:menaquinone oxidoreductase. We present a detailed biochemical characterization of the aerobic respiratory chains from Mtb and show that phenothiazine analogs specifically inhibit NADH:menaquinone oxidoreductase activity. The emergence of drug-resistant strains of Mtb has prompted a search for antimycobacterial agents. Several phenothiazines analogs are highly tuberculocidal in vitro, suppress Mtb growth in a mouse model of acute infection, and represent lead compounds that may give rise to a class of selective antibiotics.


Related Papers

No related papers found

Powered by citation graph analysis